MktsMarkets

Immunome, Inc.
NASDAQ: IMNMKey statistics
IMNM News
Stories mentioning IMNM from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 4,015 | 2,926 | 2,738 | 2,910 | 2,364 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 46,381 | 50,770 | 49,193 | 40,451 | 36,872 | 47,890 | 37,200 | 29,083 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 59,331 | 72,861 | 60,138 | 50,493 | 47,562 | 85,708 | 53,432 | 42,373 |
| Operating Income (Loss) | (59,331) | (72,861) | (60,138) | (46,478) | (44,636) | (82,970) | (50,522) | (40,009) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (53,839) | (69,900) | (57,457) | (43,397) | (41,640) | (80,249) | (47,100) | (36,122) |
| Earnings Per Share (Basic) | (0.48) | (0.80) | (0.65) | (0.50) | (0.52) | (1.37) | (0.78) | (0.60) |
| Earnings Per Share (Diluted) | (0.48) | (0.80) | (0.65) | (0.50) | (0.52) | (1.37) | (0.78) | (0.60) |
| Weighted Average Shares Outstanding (Basic) | 113,137 | 87,351 | 87,958 | 87,011 | 79,410 | 58,639 | 60,205 | 59,937 |
| Weighted Average Shares Outstanding (Diluted) | 113,137 | 87,351 | 87,958 | 87,011 | 79,410 | 58,639 | 60,205 | 59,937 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About IMNM
Immunome, Inc. (NASDAQ: IMNM) is a stock listed on the Nasdaq Stock Market under the ticker symbol IMNM. It last traded at $18.77 (Nov 13, 2026, 4:00 PM ET), up 0.4% on the day. That gives Immunome a market capitalisation of $2.2B.
Over the past 52 weeks IMNM has traded between $16.11 and $30.06.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $53.8M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $0 | -$53.8M | — |
| Dec 31, 2025 | $0 | -$69.9M | — |
| Sep 30, 2025 | $0 | -$57.5M | — |
| Jun 30, 2025 | $4.0M | -$43.4M | -1080.9% |
From Immunome’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…